The next generation in devices that
relieve blood vessel blocks will dissolve within a couple of years.
The Apollo Hospitals, one of the six
centres in India
to be part of a global trial on using drug-eluting bio-resorbable stents, are
the first in Chennai to use the product.
The device works like a regular stent by
restoring blood flow to a clogged vessel. It also contains a drug that is
slowly released to help the healing process.
But what stands out is the fact that the
stent dissolves harmlessly inside the blood vessel and restores flexibility of
the affected vessel.
Mathew Samuel Kalarickal, director,
Interventional Cardiology, Apollo Hospitals, Chennai, during a media
interaction on Tuesday said the bio-absorbable stent, which initially propped
up the blood vessel, aided the healing process and, after a while, disappeared
from the body.
In this aspect, it scores tremendously
over the previous generation of drug-eluting stents that leave the metal
support inside the blood vessel, additionally requiring the patient to be on
blood-thinner drugs for life.
“Leaving a metal stent in the coronaries
always was an anxiety for us, even though the medicated stent has proved its
safety and efficacy. It was our wish to have a device that could provide the
necessary scaffolding, deliver the medications, and dissolve without leaving
any metal trace in the body,” Dr. Kalarickal said.
Abbott's ABSORB stent is made of
polylactide, a bio-compatible material being used in dissolving sutures.
The product, which was currently
available for coronary vessel use only, had received the CE mark of approval in
Europe and this would allow it to be marketed,
Dr. Kalarickal said.
Sai Satish, consultant interventional
cardiologist, Apollo Hospitals, explained that the hospital had implanted the
stent successfully in two male patients with coronary artery disease, having
been chosen to be part of the ABSORB EXTEND global trial to study the use of
the product in about 1,000 patients at 100 centres.
To date, up to 200 patients have
received the device, including 30 patients who have had the device put in four
years ago.
The study showed that patients who had
the stent experienced no blood clots due to the presence of the foreign body,
and that the treated vessels were able to expand and contract without being
restricted by a permanent implant — indicating that the device had dissolved.
Apollo Hospitals chairman Pratap Reddy
said the stent was part of the group's endeavour to use cutting-edge technology
to give the best possible outcomes for coronary artery disease.
http://www.thehindu.com/news/cities/Chennai/article1100553.ece
The next generation in devices that
relieve blood vessel blocks will dissolve within a couple of years.
The Apollo Hospitals, one of the six
centres in India
to be part of a global trial on using drug-eluting bio-resorbable stents, are
the first in Chennai to use the product.
The device works like a regular stent by
restoring blood flow to a clogged vessel. It also contains a drug that is
slowly released to help the healing process.
But what stands out is the fact that the
stent dissolves harmlessly inside the blood vessel and restores flexibility of
the affected vessel.
Mathew Samuel Kalarickal, director,
Interventional Cardiology, Apollo Hospitals, Chennai, during a media
interaction on Tuesday said the bio-absorbable stent, which initially propped
up the blood vessel, aided the healing process and, after a while, disappeared
from the body.
In this aspect, it scores tremendously
over the previous generation of drug-eluting stents that leave the metal
support inside the blood vessel, additionally requiring the patient to be on
blood-thinner drugs for life.
“Leaving a metal stent in the coronaries
always was an anxiety for us, even though the medicated stent has proved its
safety and efficacy. It was our wish to have a device that could provide the
necessary scaffolding, deliver the medications, and dissolve without leaving
any metal trace in the body,” Dr. Kalarickal said.
Abbott's ABSORB stent is made of
polylactide, a bio-compatible material being used in dissolving sutures.
The product, which was currently
available for coronary vessel use only, had received the CE mark of approval in
Europe and this would allow it to be marketed,
Dr. Kalarickal said.
Sai Satish, consultant interventional
cardiologist, Apollo Hospitals, explained that the hospital had implanted the
stent successfully in two male patients with coronary artery disease, having
been chosen to be part of the ABSORB EXTEND global trial to study the use of
the product in about 1,000 patients at 100 centres.
To date, up to 200 patients have
received the device, including 30 patients who have had the device put in four
years ago.
The study showed that patients who had
the stent experienced no blood clots due to the presence of the foreign body,
and that the treated vessels were able to expand and contract without being
restricted by a permanent implant — indicating that the device had dissolved.
Apollo Hospitals chairman Pratap Reddy
said the stent was part of the group's endeavour to use cutting-edge technology
to give the best possible outcomes for coronary artery disease.
http://www.thehindu.com/news/cities/Chennai/article1100553.ece
The next generation in devices that
relieve blood vessel blocks will dissolve within a couple of years.
The Apollo Hospitals, one of the six
centres in India
to be part of a global trial on using drug-eluting bio-resorbable stents, are
the first in Chennai to use the product.
The device works like a regular stent by
restoring blood flow to a clogged vessel. It also contains a drug that is
slowly released to help the healing process.
But what stands out is the fact that the
stent dissolves harmlessly inside the blood vessel and restores flexibility of
the affected vessel.
Mathew Samuel Kalarickal, director,
Interventional Cardiology, Apollo Hospitals, Chennai, during a media
interaction on Tuesday said the bio-absorbable stent, which initially propped
up the blood vessel, aided the healing process and, after a while, disappeared
from the body.
In this aspect, it scores tremendously
over the previous generation of drug-eluting stents that leave the metal
support inside the blood vessel, additionally requiring the patient to be on
blood-thinner drugs for life.
“Leaving a metal stent in the coronaries
always was an anxiety for us, even though the medicated stent has proved its
safety and efficacy. It was our wish to have a device that could provide the
necessary scaffolding, deliver the medications, and dissolve without leaving
any metal trace in the body,” Dr. Kalarickal said.
Abbott's ABSORB stent is made of
polylactide, a bio-compatible material being used in dissolving sutures.
The product, which was currently
available for coronary vessel use only, had received the CE mark of approval in
Europe and this would allow it to be marketed,
Dr. Kalarickal said.
Sai Satish, consultant interventional
cardiologist, Apollo Hospitals, explained that the hospital had implanted the
stent successfully in two male patients with coronary artery disease, having
been chosen to be part of the ABSORB EXTEND global trial to study the use of
the product in about 1,000 patients at 100 centres.
To date, up to 200 patients have
received the device, including 30 patients who have had the device put in four
years ago.
The study showed that patients who had
the stent experienced no blood clots due to the presence of the foreign body,
and that the treated vessels were able to expand and contract without being
restricted by a permanent implant — indicating that the device had dissolved.
Apollo Hospitals chairman Pratap Reddy
said the stent was part of the group's endeavour to use cutting-edge technology
to give the best possible outcomes for coronary artery disease.
http://www.thehindu.com/news/cities/Chennai/article1100553.ece
The next generation in devices that
relieve blood vessel blocks will dissolve within a couple of years.
The Apollo Hospitals, one of the six
centres in India
to be part of a global trial on using drug-eluting bio-resorbable stents, are
the first in Chennai to use the product.
The device works like a regular stent by
restoring blood flow to a clogged vessel. It also contains a drug that is
slowly released to help the healing process.
But what stands out is the fact that the
stent dissolves harmlessly inside the blood vessel and restores flexibility of
the affected vessel.
Mathew Samuel Kalarickal, director,
Interventional Cardiology, Apollo Hospitals, Chennai, during a media
interaction on Tuesday said the bio-absorbable stent, which initially propped
up the blood vessel, aided the healing process and, after a while, disappeared
from the body.
In this aspect, it scores tremendously
over the previous generation of drug-eluting stents that leave the metal
support inside the blood vessel, additionally requiring the patient to be on
blood-thinner drugs for life.
“Leaving a metal stent in the coronaries
always was an anxiety for us, even though the medicated stent has proved its
safety and efficacy. It was our wish to have a device that could provide the
necessary scaffolding, deliver the medications, and dissolve without leaving
any metal trace in the body,” Dr. Kalarickal said.
Abbott's ABSORB stent is made of
polylactide, a bio-compatible material being used in dissolving sutures.
The product, which was currently
available for coronary vessel use only, had received the CE mark of approval in
Europe and this would allow it to be marketed,
Dr. Kalarickal said.
Sai Satish, consultant interventional
cardiologist, Apollo Hospitals, explained that the hospital had implanted the
stent successfully in two male patients with coronary artery disease, having
been chosen to be part of the ABSORB EXTEND global trial to study the use of
the product in about 1,000 patients at 100 centres.
To date, up to 200 patients have
received the device, including 30 patients who have had the device put in four
years ago.
The study showed that patients who had
the stent experienced no blood clots due to the presence of the foreign body,
and that the treated vessels were able to expand and contract without being
restricted by a permanent implant — indicating that the device had dissolved.
Apollo Hospitals chairman Pratap Reddy
said the stent was part of the group's endeavour to use cutting-edge technology
to give the best possible outcomes for coronary artery disease.
http://www.thehindu.com/news/cities/Chennai/article1100553.ece
The next generation in devices that
relieve blood vessel blocks will dissolve within a couple of years.
The Apollo Hospitals, one of the six
centres in India
to be part of a global trial on using drug-eluting bio-resorbable stents, are
the first in Chennai to use the product.
The device works like a regular stent by
restoring blood flow to a clogged vessel. It also contains a drug that is
slowly released to help the healing process.
But what stands out is the fact that the
stent dissolves harmlessly inside the blood vessel and restores flexibility of
the affected vessel.
Mathew Samuel Kalarickal, director,
Interventional Cardiology, Apollo Hospitals, Chennai, during a media
interaction on Tuesday said the bio-absorbable stent, which initially propped
up the blood vessel, aided the healing process and, after a while, disappeared
from the body.
In this aspect, it scores tremendously
over the previous generation of drug-eluting stents that leave the metal
support inside the blood vessel, additionally requiring the patient to be on
blood-thinner drugs for life.
“Leaving a metal stent in the coronaries
always was an anxiety for us, even though the medicated stent has proved its
safety and efficacy. It was our wish to have a device that could provide the
necessary scaffolding, deliver the medications, and dissolve without leaving
any metal trace in the body,” Dr. Kalarickal said.
Abbott's ABSORB stent is made of
polylactide, a bio-compatible material being used in dissolving sutures.
The product, which was currently
available for coronary vessel use only, had received the CE mark of approval in
Europe and this would allow it to be marketed,
Dr. Kalarickal said.
Sai Satish, consultant interventional
cardiologist, Apollo Hospitals, explained that the hospital had implanted the
stent successfully in two male patients with coronary artery disease, having
been chosen to be part of the ABSORB EXTEND global trial to study the use of
the product in about 1,000 patients at 100 centres.
To date, up to 200 patients have
received the device, including 30 patients who have had the device put in four
years ago.
The study showed that patients who had
the stent experienced no blood clots due to the presence of the foreign body,
and that the treated vessels were able to expand and contract without being
restricted by a permanent implant — indicating that the device had dissolved.
Apollo Hospitals chairman Pratap Reddy
said the stent was part of the group's endeavour to use cutting-edge technology
to give the best possible outcomes for coronary artery disease.
http://www.thehindu.com/news/cities/Chennai/article1100553.ece
The next generation in devices that
relieve blood vessel blocks will dissolve within a couple of years.
The Apollo Hospitals, one of the six
centres in India
to be part of a global trial on using drug-eluting bio-resorbable stents, are
the first in Chennai to use the product.
The device works like a regular stent by
restoring blood flow to a clogged vessel. It also contains a drug that is
slowly released to help the healing process.
But what stands out is the fact that the
stent dissolves harmlessly inside the blood vessel and restores flexibility of
the affected vessel.
Mathew Samuel Kalarickal, director,
Interventional Cardiology, Apollo Hospitals, Chennai, during a media
interaction on Tuesday said the bio-absorbable stent, which initially propped
up the blood vessel, aided the healing process and, after a while, disappeared
from the body.
In this aspect, it scores tremendously
over the previous generation of drug-eluting stents that leave the metal
support inside the blood vessel, additionally requiring the patient to be on
blood-thinner drugs for life.
“Leaving a metal stent in the coronaries
always was an anxiety for us, even though the medicated stent has proved its
safety and efficacy. It was our wish to have a device that could provide the
necessary scaffolding, deliver the medications, and dissolve without leaving
any metal trace in the body,” Dr. Kalarickal said.
Abbott's ABSORB stent is made of
polylactide, a bio-compatible material being used in dissolving sutures.
The product, which was currently
available for coronary vessel use only, had received the CE mark of approval in
Europe and this would allow it to be marketed,
Dr. Kalarickal said.
Sai Satish, consultant interventional
cardiologist, Apollo Hospitals, explained that the hospital had implanted the
stent successfully in two male patients with coronary artery disease, having
been chosen to be part of the ABSORB EXTEND global trial to study the use of
the product in about 1,000 patients at 100 centres.
To date, up to 200 patients have
received the device, including 30 patients who have had the device put in four
years ago.
The study showed that patients who had
the stent experienced no blood clots due to the presence of the foreign body,
and that the treated vessels were able to expand and contract without being
restricted by a permanent implant — indicating that the device had dissolved.
Apollo Hospitals chairman Pratap Reddy
said the stent was part of the group's endeavour to use cutting-edge technology
to give the best possible outcomes for coronary artery disease.
http://www.thehindu.com/news/cities/Chennai/article1100553.ece
The next generation in devices that
relieve blood vessel blocks will dissolve within a couple of years.
The Apollo Hospitals, one of the six
centres in India
to be part of a global trial on using drug-eluting bio-resorbable stents, are
the first in Chennai to use the product.
The device works like a regular stent by
restoring blood flow to a clogged vessel. It also contains a drug that is
slowly released to help the healing process.
But what stands out is the fact that the
stent dissolves harmlessly inside the blood vessel and restores flexibility of
the affected vessel.
Mathew Samuel Kalarickal, director,
Interventional Cardiology, Apollo Hospitals, Chennai, during a media
interaction on Tuesday said the bio-absorbable stent, which initially propped
up the blood vessel, aided the healing process and, after a while, disappeared
from the body.
In this aspect, it scores tremendously
over the previous generation of drug-eluting stents that leave the metal
support inside the blood vessel, additionally requiring the patient to be on
blood-thinner drugs for life.
“Leaving a metal stent in the coronaries
always was an anxiety for us, even though the medicated stent has proved its
safety and efficacy. It was our wish to have a device that could provide the
necessary scaffolding, deliver the medications, and dissolve without leaving
any metal trace in the body,” Dr. Kalarickal said.
Abbott's ABSORB stent is made of
polylactide, a bio-compatible material being used in dissolving sutures.
The product, which was currently
available for coronary vessel use only, had received the CE mark of approval in
Europe and this would allow it to be marketed,
Dr. Kalarickal said.
Sai Satish, consultant interventional
cardiologist, Apollo Hospitals, explained that the hospital had implanted the
stent successfully in two male patients with coronary artery disease, having
been chosen to be part of the ABSORB EXTEND global trial to study the use of
the product in about 1,000 patients at 100 centres.
To date, up to 200 patients have
received the device, including 30 patients who have had the device put in four
years ago.
The study showed that patients who had
the stent experienced no blood clots due to the presence of the foreign body,
and that the treated vessels were able to expand and contract without being
restricted by a permanent implant — indicating that the device had dissolved.
Apollo Hospitals chairman Pratap Reddy
said the stent was part of the group's endeavour to use cutting-edge technology
to give the best possible outcomes for coronary artery disease.
http://www.thehindu.com/news/cities/Chennai/article1100553.ece
The next generation in devices that
relieve blood vessel blocks will dissolve within a couple of years.
The Apollo Hospitals, one of the six
centres in India
to be part of a global trial on using drug-eluting bio-resorbable stents, are
the first in Chennai to use the product.
The device works like a regular stent by
restoring blood flow to a clogged vessel. It also contains a drug that is
slowly released to help the healing process.
But what stands out is the fact that the
stent dissolves harmlessly inside the blood vessel and restores flexibility of
the affected vessel.
Mathew Samuel Kalarickal, director,
Interventional Cardiology, Apollo Hospitals, Chennai, during a media
interaction on Tuesday said the bio-absorbable stent, which initially propped
up the blood vessel, aided the healing process and, after a while, disappeared
from the body.
In this aspect, it scores tremendously
over the previous generation of drug-eluting stents that leave the metal
support inside the blood vessel, additionally requiring the patient to be on
blood-thinner drugs for life.
“Leaving a metal stent in the coronaries
always was an anxiety for us, even though the medicated stent has proved its
safety and efficacy. It was our wish to have a device that could provide the
necessary scaffolding, deliver the medications, and dissolve without leaving
any metal trace in the body,” Dr. Kalarickal said.
Abbott's ABSORB stent is made of
polylactide, a bio-compatible material being used in dissolving sutures.
The product, which was currently
available for coronary vessel use only, had received the CE mark of approval in
Europe and this would allow it to be marketed,
Dr. Kalarickal said.
Sai Satish, consultant interventional
cardiologist, Apollo Hospitals, explained that the hospital had implanted the
stent successfully in two male patients with coronary artery disease, having
been chosen to be part of the ABSORB EXTEND global trial to study the use of
the product in about 1,000 patients at 100 centres.
To date, up to 200 patients have
received the device, including 30 patients who have had the device put in four
years ago.
The study showed that patients who had
the stent experienced no blood clots due to the presence of the foreign body,
and that the treated vessels were able to expand and contract without being
restricted by a permanent implant — indicating that the device had dissolved.
Apollo Hospitals chairman Pratap Reddy
said the stent was part of the group's endeavour to use cutting-edge technology
to give the best possible outcomes for coronary artery disease.
http://www.thehindu.com/news/cities/Chennai/article1100553.ece
The next generation in devices that
relieve blood vessel blocks will dissolve within a couple of years.
The Apollo Hospitals, one of the six
centres in India
to be part of a global trial on using drug-eluting bio-resorbable stents, are
the first in Chennai to use the product.
The device works like a regular stent by
restoring blood flow to a clogged vessel. It also contains a drug that is
slowly released to help the healing process.
But what stands out is the fact that the
stent dissolves harmlessly inside the blood vessel and restores flexibility of
the affected vessel.
Mathew Samuel Kalarickal, director,
Interventional Cardiology, Apollo Hospitals, Chennai, during a media
interaction on Tuesday said the bio-absorbable stent, which initially propped
up the blood vessel, aided the healing process and, after a while, disappeared
from the body.
In this aspect, it scores tremendously
over the previous generation of drug-eluting stents that leave the metal
support inside the blood vessel, additionally requiring the patient to be on
blood-thinner drugs for life.
“Leaving a metal stent in the coronaries
always was an anxiety for us, even though the medicated stent has proved its
safety and efficacy. It was our wish to have a device that could provide the
necessary scaffolding, deliver the medications, and dissolve without leaving
any metal trace in the body,” Dr. Kalarickal said.
Abbott's ABSORB stent is made of
polylactide, a bio-compatible material being used in dissolving sutures.
The product, which was currently
available for coronary vessel use only, had received the CE mark of approval in
Europe and this would allow it to be marketed,
Dr. Kalarickal said.
Sai Satish, consultant interventional
cardiologist, Apollo Hospitals, explained that the hospital had implanted the
stent successfully in two male patients with coronary artery disease, having
been chosen to be part of the ABSORB EXTEND global trial to study the use of
the product in about 1,000 patients at 100 centres.
To date, up to 200 patients have
received the device, including 30 patients who have had the device put in four
years ago.
The study showed that patients who had
the stent experienced no blood clots due to the presence of the foreign body,
and that the treated vessels were able to expand and contract without being
restricted by a permanent implant — indicating that the device had dissolved.
Apollo Hospitals chairman Pratap Reddy
said the stent was part of the group's endeavour to use cutting-edge technology
to give the best possible outcomes for coronary artery disease.
http://www.thehindu.com/news/cities/Chennai/article1100553.ece
The next generation in devices that
relieve blood vessel blocks will dissolve within a couple of years.
The Apollo Hospitals, one of the six
centres in India
to be part of a global trial on using drug-eluting bio-resorbable stents, are
the first in Chennai to use the product.
